Search Results - "OSBORNE, C. Kent"

Mechanisms of endocrine resistance in breast cancer by Osborne, C Kent, Schiff, Rachel

“…The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and progression. Endocrine therapy to block the ER pathway is highly…”
Get full text

Towards personalized treatment for early stage HER2-positive breast cancer by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

“…Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized…”
Get full text

Targeting HER2 for the Treatment of Breast Cancer by Rimawi, Mothaffar F, Schiff, Rachel, Osborne, C. Kent

“…HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. Treatment with the…”
Get full text

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer by Burstein, Matthew D, Tsimelzon, Anna, Poage, Graham M, Covington, Kyle R, Contreras, Alejandro, Fuqua, Suzanne A W, Savage, Michelle I, Osborne, C Kent, Hilsenbeck, Susan G, Chang, Jenny C, Mills, Gordon B, Lau, Ching C, Brown, Powel H

“…Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and…”
Get full text

Metastasis dormancy in estrogen receptor-positive breast cancer by Zhang, Xiang H-F, Giuliano, Mario, Trivedi, Meghana V, Schiff, Rachel, Osborne, C Kent

“…About 20% to 40% of patients with breast cancer eventually develop recurrences in distant organs, which are often not detected until years to decades after the…”
Get full text

The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells by Wang, Hai, Yu, Cuijuan, Gao, Xia, Welte, Thomas, Muscarella, Aaron M., Tian, Lin, Zhao, Hong, Zhao, Zhen, Du, Shiyu, Tao, Jianning, Lee, Brendan, Westbrook, Thomas F., Wong, Stephen T.C., Jin, Xin, Rosen, Jeffrey M., Osborne, C. Kent, Zhang, Xiang H.-F.

“…Breast cancer bone micrometastases can remain asymptomatic for years before progressing into overt lesions. The biology of this process, including the…”
Get full text

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance by Arpino, Grazia, Wiechmann, Lisa, Osborne, C. Kent, Schiff, Rachel

“…Breast cancer evolution and tumor progression are governed by the complex interactions between steroid receptor [estrogen receptor (ER) and progesterone…”
Get full text

Treatment of HER2-positive breast cancer: current status and future perspectives by Arteaga, Carlos L., Sliwkowski, Mark X., Osborne, C. Kent, Perez, Edith A., Puglisi, Fabio, Gianni, Luca

“…Despite the advent of HER2-directed therapies, many patients with HER2-positive early stage breast cancer relapse and die of this disease. Trials to define,…”
Get full text

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 by RIMAWI, Mothaffar F, MAYER, Ingrid A, SCHIFF, Rachel, KENT OSBORNE, C, CHANG, Jenny C, FORERO, Andres, NANDA, Rita, GOETZ, Matthew P, RODRIGUEZ, Angel A, PAVLICK, Anne C, TAO WANG, HILSENBECK, Susan G, GUTIERREZ, Carolina

“…We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway…”
Get full text

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial by Johnston, Stephen, Puhalla, Shannon, Wheatley, Duncan, Ring, Alistair, Barry, Peter, Holcombe, Chris, Boileau, Jean Francois, Provencher, Louise, Robidoux, André, Rimawi, Mothaffar, McIntosh, Stuart A, Shalaby, Ibrahim, Stein, Robert C, Thirlwell, Michael, Dolling, David, Morden, James, Snowdon, Claire, Perry, Sophie, Cornman, Chester, Batten, Leona M, Jeffs, Lisa K, Dodson, Andrew, Martins, Vera, Modi, Arjun, Osborne, C Kent, Pogue-Geile, Katherine L, Cheang, Maggie Chon U, Wolmark, Norman, Julian, Thomas B, Fisher, Kate, MacKenzie, Mairead, Wilcox, Maggie, Huang Bartlett, Cynthia, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M, Jacobs, Samuel A

“…CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II…”
Get full text

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer by Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Kent Osborne, C., Schiff, Rachel

“…Purpose Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by…”
Get full text

Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer by Mouabbi, Jason A., Osborne, C. Kent, Schiff, Rachel, Rimawi, Mothaffar F.

“…Estrogen receptor (ER) is the major driver of most metastatic breast cancers (mBCs). Endocrine therapy (ET) is the most effective treatment for ER + mBC, but…”
Get full text

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors…”
Get full text

An epigenomic approach to therapy for tamoxifen-resistant breast cancer by Feng, Qin, Zhang, Zheng, Shea, Martin J, Creighton, Chad J, Coarfa, Cristian, Hilsenbeck, Susan G, Lanz, Rainer, He, Bin, Wang, Lei, Fu, Xiaoyong, Nardone, Agostina, Song, Yongcheng, Bradner, James, Mitsiades, Nicholas, Mitsiades, Constantine S, Osborne, C Kent, Schiff, Rachel, O'Malley, Bert W

“…Tamoxifen has been a frontline treatment for estrogen receptor alpha （ERα）-positive breast tumors in premenopausal women. However, resistance to tamoxifen…”
Get full text

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers by DAVE, Bhuvanesh, MIGLIACCIO, Ilenia, RIMAWI, Mothaffar, SCHIFF, Rachel, ARTEAGA, Carlos, KENT OSBORNE, C, CHANG, Jenny C, GUTIERREZ, M. Carolina, WU, Meng-Fen, CHAMNESS, Gary C, WONG, Helen, NARASANNA, Archana, CHAKRABARTY, Anindita, HILSENBECK, Susan G, JIAN HUANG

“…Phosphatase and tensin homolog (PTEN) loss or activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab resistance…”
Get full text

The changing role of ER in endocrine resistance by Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel

“…Abstract Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although endocrine therapy targeting ER is highly…”
Get full text

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer by Harvey, Jennet M, Clark, Gary M, Osborne, C Kent, Allred, D Craig

“…Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the…”
Get full text

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy by Li, Xiaoxian, Lewis, Michael T., Huang, Jian, Gutierrez, Carolina, Osborne, C. Kent, Wu, Meng-Fen, Hilsenbeck, Susan G., Pavlick, Anne, Zhang, Xiaomei, Chamness, Gary C., Wong, Helen, Rosen, Jeffrey, Chang, Jenny C.

“…Background Tumorigenic breast cancer cells that express high levels of CD44 and low or undetectable levels of CD24 (CD44>/CD24>/low) may be resistant to…”
Get full text

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer by Fu, Xiaoyong, Osborne, C. Kent, Schiff, Rachel

“…Abstract PI3K is a central node mediating growth factor receptor signaling. With its downstream effectors such as AKT and mTOR, and its crosstalk with the…”
Get full text

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer by Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, C Kent

“…Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients…”
Get full text